Early and intermediate stage Hodgkin's lymphoma - Report from the Swedish National Care Programme

European Journal of Haematology

Volumn 70, Issue 3, 2003, Pages 172-180

  Molin, Daniel ^a,b   Enblad, Gunilla ^a   Gustavsson, Anita ^a   Ekman, Tor ^a   Erlanson, Martin ^a   Haapaniemi, Eva ^a   Glimelius, Bengt ^a  

^a Department of Oncology ^*  (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Early stage; Hodgkin's lymphoma; Intermediate stage; Prognosis; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HEALTH PROGRAM; HODGKIN DISEASE; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SWEDEN;

EID: 0038813810     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00030.x     Document Type: Article

References (37)

1. MAUCH PM, ARMITAGE JO, DIEHL V, et al. Hodgkin's Disease. Philadelphia: Lippincott, Williams & Wilkins, 1999.
2. RAEMAEKERS J, KLUIN-NELEMANS H, TEODOROVIC I, et al. The achievements of the EORTC Lymphoma Group. Eur J Cancer 2002;38(Suppl. 4):107-113.
3. HANCOCK SL, TUCKER MA, HOPPE RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993:85:25-31.
4. AISENBERG AC, FINKELSTEIN DM, DOPPKE KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997:79:1203-1210.
5. DEVITA VT, Late sequelae of treatment of Hodgkin's disease. Curr Opin Oncol 1997:9:428-431.
6. HENRY-AMAR M, JOLY F. Late complications after Hodgkin's disease. Ann Oncol 1996;7(Suppl 4):115-126.
7. TRAVIS LB, GOSPODAROWICZ M, CURTIS RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192.
8. GLIMELIUS B, ENBLAD G, KALKNER M, et al. Treatment of Hodgkin's disease: the Swedish National Care Programme experience. Leuk Lymphoma 1996;21:71-78.
9. GLIMELIUS B, KALKNER M, ENBLAD G, et al. Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. Swedish Lymphoma Study Group. Ann Oncol 1994;5:809-816.
10. HASENCLEVER D, DIEHL V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
11. FRANKLIN J, PAULUS U, LIEBERZ D, et al. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group. Ann Oncol 2000;11:617-623.
12. LUKES RJCL, CRAVER LF, HALL TC, et al. Report of the nomenclature committee. Cancer Res 1966;26:1311.
13. CARBONE PP, KAPLAN HS, MUSSHOFF K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
14. AMINI RM, ENBLAD G, GUSTAVSSON A, et al. Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience. Eur J Haematol 2000;65:379-389.
15. BRANDT L, KIMBY E, NYGREN P, et al. A systematic overview of chemotherapy effects in Hodgkin's disease. Acta Oncol 2001;40:185-197.
16. JOSTING A, DIEHL V. Early-stage Hodgkin's disease. Curr Oncol Rep 2001;3:279-284.
17. ZITTOUN R, AUDEBERT A, HOERNI B, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 1985;3:207-214.
18. BONFANTE V, VIVIANI, S, DEVIZZI, L et al. Ten-years experience with ABVD plus radiotherapy: subtotal nodal (STNI) vs involved-field (IFRT) in early stage Hodgkin's disease. Proc Am Soc Clin Oncol. 2001;20:281a (Abstr 1120).
19. ENGERT A, SCHILLER, P, PFISTNER, B et al. Involved field (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP/ABVD in patients with intermediate-stage HD. Blood 2001;98:768a (Abstr 3199).
20. VLACHAKI MT, HAGEMEISTER FB, FULLER LM, et al. Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression. Int J Radiat Oncol Biol Phys 1997;38593-599.
21. MAUCH PM. Management of early stage Hodgkin's disease: the role of radiation therapy and/or chemotherapy. Baillieres Clin Haematol 1996;9:531-541.
22. ENBLAD G, GLIMELIUS B, SUNDSTROM C. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol 1991;2:297-302.
23. SCOTT JS, DAWSON AA, PROCTOR SJ, et al. The place of staging laparotomy in the management of Hodgkin's disease. Clin Radiol 1984;35:261-263.
24. BRADA M, EASTON DF, HORWICH A, et al. Clinical presentation as a predictor of laparotomy findings in supradiaphragmatic stage I and II Hodgkin's disease. Radiother Oncol 1986;5:15-22.
25. SPECHT L, LAURITZEN AF, NORDENTOFT AM, ANDERSEN PK, CHRISTENSEN BE, HIPPE E, HOU-JENSEN K, NISSEN NI. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. The Danish National Hodgkin Study Group. Cancer 1990;65:2594-2601.
26. ENBLAD G, SUNDSTROM C, GLIMELIUS B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol. 1993;11:187-193.
27. VON WASIELEWSKI R, SETH S, FRANKLIN J, et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000;95:1207-1213.
28. MOLIN D, FISCHER M, XIANG Z, et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001;114:616-623.
29. SIEBER M, TESCH H, PFISTNER B, et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 2002;20:476-484.
30. BRIERLEY JD, RATHMELL AJ, GOSPODAROWICZ MK, et al. Late relapse after treatment for clinical stage I and II Hodgkin's disease. Cancer 1997;79:1422-1427.
31. CHARLTON BG, TAYLOR PR, PROCTOR SJ. The PACE (population-adjusted clinical epidemiology) strategy: a new approach to multi-centred clinical research. Qjm 1997;90:147-151.
32. TAYLOR PR, ANGUS B, OWEN JP, et al. Hodgkin's disease: a population-adjusted clinical epidemiology study (PACE) of management at presentation. Northern Region Lymphoma Group. Qjm 1998;91:131-139.
33. PROCTOR SJ, TAYLOR P, MACKIE MJ, et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk Lymphoma 1992;7: 17-20.
34. PROCTOR SJ, TAYLOR P, DONNAN P, et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer 1991;27:624-629.
35. MOODY AM, PRATT J, HUDSON GV, et al. British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease. Clin Oncol 2001;13:262-268.
36. HORNING SJ, HOPPE RT, MASON J, et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and Neomycin chemotherapy and regional irradiation. J Clin Oncol 1997;15:1736-17344.
37. HOPPE RT, COLEMAN CN, COX RS, et al. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982;59:455-465.